AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026, 4:50 PM ET Aldeyra received a Nasdaq notice that its closing bid price was below the $1.00 minimum for 30 consecutive business days, with a compliance period until May 17, 2027. AI-generated summary · Source: SEC filing
Nasdaq: $ALDXReproxalap appealFDRR filed October 26 · OND meeting Q4 2026Regulatory and funding risk

ALDX Stock Hub: Aldeyra Therapeutics News, Reproxalap and FDA Appeal

Aldeyra filed its formal appeal regarding reproxalap on October 26, 2026, and expects a meeting with the FDA Office of New Drugs (OND) in Q4. September 30 cash and equivalents were $40,974,979. Nasdaq notified Aldeyra of a minimum-bid deficiency on November 17. The notice leaves the listing effective, with an initial compliance period to May 17, 2027. November 5 Form 10-Q · November 17 Form 8-K.

Last updated: November 18, 2026 · Financial period: quarter ended September 30, 2026 · Currency: USD
Full research report · PDF
Aldeyra Therapeutics ($ALDX), research updated November 9, 2026
The November 9, 2026 edition adds the third-quarter 2026 results filed on November 5, the Form 8-K of November 9 on ADX-2191 in primary vitreoretinal lymphoma (PVRL) and a re-examined Health Score, alongside the reproxalap complete response letter (CRL) and appeal, subsequent new drug application (NDA) requirements, ADX-2191, cash and dilution. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next regulatory milestone · company expectation
Q4 2026 · Office of New Drugs meeting

The formal dispute resolution request (FDRR) challenges the March 16 complete response letter. The November 5 filing states a meeting window. Any appeal decision, subsequent application and FDA action would follow separate steps. September quarterly filing · Appeal and resubmission.

Latest: Nasdaq issued its minimum-bid notice on November 17. Aldeyra has until May 17, 2027 in its initial compliance period. November 17 Form 8-K.
Aldeyra Therapeutics ALDX daily stock chart
Daily chart $ALDX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

ALDX stock at a glance

Chart analysis · JC
Technical chart analysis of $ALDX with bull and bear scenarios on JC Just Charts.
Cash and equivalents · September 30
$40.975M
$40,974,979 as of September 30, 2026. Balance sheet.
Debt obligations · September 30
$0
Hercules repaid April 1; not a statement about future funding needs.
Net loss · Q3 2026
$3.763M
$3,762,964 for the September quarter and $12,665,856 for the first nine months of 2026. Income statement.
R&D expense · Q3 2026
$1.837M
$1,837,390 for the September quarter. Income statement.
Common shares · November 3
60.357M
60,356,541 on the Q3 Form 10-Q cover; no shares sold under the $75M Jefferies at-the-market (ATM) program through September 30.
Operational cash runway
Into 2029
November 5 company outlook excludes potential licensing and product revenue. The November 9 filing disclosed additional development and funding risks. Form 10-Q · November 9 Form 8-K.
OND meeting window
Q4 2026
FDRR submitted October 26; company expectation, no announced decision day and not a Prescription Drug User Fee Act (PDUFA) goal date.

Where Aldeyra Therapeutics stands now

Aldeyra is pursuing its formal dispute over the March reproxalap complete response letter. The November 5 filing reports a Q4 meeting expectation and $13,824,010 of operating cash use through September. It projects funding into 2029 under its operating plan, excluding potential licensing and product revenue. November 5 Form 10-Q · Cash and operating expenses.

On November 9 Aldeyra disclosed a request to change the FDA division reviewing the ADX-2191 investigational new drug application (IND) for PVRL and withdrew the trial protocol previously agreed under the Special Protocol Assessment (SPA). It does not expect to start the planned trial while the request is pending. The company disclosed a separate Nasdaq notice on November 17. November 9 Form 8-K · November 17 Form 8-K.

Main risk: any appeal decision, subsequent application and potential licensing agreement carry different conditions and timelines.

The constructive case

Merlintrader reading: a favorable dispute outcome could clarify a later application step while Aldeyra’s current balance sheet supports its operating plan.

The cautious case

Merlintrader reading: additional evidence or trial requirements could extend the timeline and raise spending, even if the company can pursue further review.

Latest ALDX news

Nov 17, 2026

Aldeyra receives Nasdaq notice on minimum bid price requirement

Aldeyra Therapeutics received a Nasdaq notice that its common stock closing bid price was below the $1.00 minimum bid price requirement for the last 30 consecutive business days. The notice has no immediate effect on the listing, and the company has until May 17, 2027, a 180 calendar day period, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. The company intends to use its best efforts to resolve the situation and continue listing on The Nasdaq Capital Market.

Nov 16, 2026

Aldeyra director Darlene Deptula-Hicks reports a share purchase

The November 16 Form 4 reports a November 12 purchase of 7,500 common shares. The transaction is designated code P.

Nov 13, 2026

Aldeyra director Richard Douglas reports a share purchase

The November 13 Form 4 reports a November 11 purchase of 200,000 common shares. The transaction is designated code P.

Nov 13, 2026

Aldeyra principal financial officer Michael Alfieri reports a share purchase

The November 13 Form 4 reports a November 11 purchase of 10,000 common shares. The transaction is designated code P.

Nov 12, 2026

AQR reports a 1.11% Aldeyra beneficial ownership position

The Schedule 13G/A reports 672,616 shares, or 1.11% of the class, as of September 30. This is a dated beneficial ownership disclosure.

Nov 10, 2026

Aldeyra posts Phase 2 atopic dermatitis trial results on ClinicalTrials.gov

Results for the Phase 2 study A Clinical Trial in Subjects With Atopic Dermatitis (Part 1), NCT05717920, were first posted on ClinicalTrials.gov on 2026-11-10. The study enrolled 8 subjects and its overall status is listed as COMPLETED. The lead sponsor is Aldeyra Therapeutics, Inc.

ALDX stock catalysts and regulatory milestones

  • October 26, 2026 — Aldeyra submitted its Formal Dispute Resolution Request, challenging the March reproxalap complete response letter. Submitted November 5 Form 10-Q.
  • November 5–6, 2026 — Aldeyra filed September results. Barclays reported a 5.48% September 30 beneficial ownership position the next day. Financial and ownership filings Form 10-Q · Schedule 13G.
  • November 9, 2026 — Aldeyra disclosed its ADX-2191 review-transfer request and withdrew the SPA trial protocol. Request pending Form 8-K.
  • November 10, 2026 — First results posted for the completed open-label ADX-629 atopic dermatitis study. Registry results Trial registry.
  • November 12, 2026 — AQR’s amended ownership filing reported 1.11% as of September 30. Dated ownership disclosure Schedule 13G/A.
  • November 13–16, 2026 — Two directors and the principal financial officer filed code P purchase disclosures for transactions on November 11 and 12. Reported purchases Douglas filing · Alfieri filing · Deptula-Hicks filing.
  • November 16, 2026 — The ADX-2191 lymphoma trial registry update lists a projected December 2027 study start. Aldeyra’s November 9 filing says it does not expect to start the trial while its review-transfer request is pending. Registry estimate and company statement Trial record · Form 8-K.
  • November 17, 2026 — Nasdaq issued a notice of noncompliance with its $1 minimum-bid rule. The notice has no immediate listing effect. Notice received Form 8-K.
  • Q4 2026 — Office of New Drugs meeting expected on the reproxalap appeal. Company window Form 10-Q.
  • May 17, 2027 — End of the initial compliance period under the Nasdaq notice. Initial listing deadline Form 8-K.

Reproxalap review and the separate development programs

The formal appeal, FDA meeting and possible subsequent resubmission are distinct stages. Aldeyra’s September-quarter filing says the AbbVie option had yet to be exercised. November 5 Form 10-Q · Appeal and next application steps · Option and payment terms.

ADX-2191 in primary vitreoretinal lymphoma remains subject to a requested review change. Results posted on November 10 for ADX-629 concern a small, completed open-label study. November 9 Form 8-K · Study registry · Other development programs.

Aldeyra Therapeutics deep dive: the full analysis

The reproxalap appeal, the reset pipeline and conditional partnership economics: a full analysis of the regulatory evidence, financial resources and remaining execution risks. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Bull, base and bear scenarios

Bull case: the appeal creates a workable evidence path

The constructive scenario begins with an Office of New Drugs assessment that gives Aldeyra a manageable route beyond the March 2026 complete response letter for reproxalap. The Formal Dispute Resolution Request was submitted October 26. A favorable outcome could clarify how the evidence may support a subsequent NDA response. Merlintrader reading: the improvement would come from a defined regulatory requirement and executable next step, rather than treating the appeal itself as marketing approval. The company still needs an acceptable application and an affirmative agency decision. September 30, 2026 Form 10-Q, filed November 5 September 29, 2026 regulatory presentation

The AbbVie option could then become more consequential if approval is achieved and the contractual exercise conditions are satisfied. It remains unexercised in the November 5 filing. Merlintrader reading: a capable potential commercial partner can improve future execution possibilities while leaving the present efficacy dispute unresolved. The option’s contingent economics are different from the cash already held by Aldeyra and from financing committed to cover any new clinical requirement. September 30, 2026 Form 10-Q, filed November 5

Base case: a funded but uncertain regulatory process

Aldeyra proceeds through formal dispute resolution while retaining a limited operating organization and substantial resources relative to its recent expenditure. September cash was approximately $41 million, with operating runway guided into 2029. The November 9 ADX-2191 regulatory reset introduces potential delays, redesign and higher costs that could shorten that outlook. Merlintrader reading: the base case contains time to pursue selected programs, but no assurance that the current plan finances every possible outcome. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

The company expects an OND meeting in Q4 2026, without an announced decision day or new PDUFA date. A request for analyses, further review or additional evidence could extend the sequence. Merlintrader reading: a procedural step can reduce uncertainty about what comes next without resolving the scientific question or creating near-term product revenue. The other pipeline assets also require independent execution and evidence. September 30, 2026 Form 10-Q, filed November 5 September 29, 2026 regulatory presentation

Bear case: evidence requirements expand while optionality remains conditional

The adverse scenario involves an unfavorable appeal outcome, substantial further studies or a regulatory route that is uneconomic to pursue. Three reproxalap CRLs already reflect recurring efficacy concerns. The ADX-2191 jurisdiction request and withdrawn SPA trial protocol add a separate development uncertainty. Merlintrader reading: more time or higher costs can consume cash while partner and product payments remain contingent. A Nasdaq compliance process also now has a deadline, separate from scientific progress. March 16, 2026 FDA complete response letter November 9, 2026 ADX-2191 regulatory disclosure November 17, 2026 Nasdaq notice disclosure

What would falsify this reading

A clear regulatory requirement could improve the assessment. An appeal outcome identifying a limited, feasible NDA response would strengthen the development case. A later accepted resubmission and affirmative decision would answer further questions. Those are distinct milestones, each requiring its own agency action. September 30, 2026 Form 10-Q, filed November 5 September 29, 2026 regulatory presentation

A substantial new evidence requirement could weaken it. A larger or longer study, an unworkable endpoint or further disagreement about the existing trials could increase time and capital needs. The November 9 PVRL disclosure separately warns of trial redesign and possible effects on other FDA interactions. November 9, 2026 ADX-2191 regulatory disclosure March 16, 2026 FDA complete response letter

Actual financing or partner execution could change the resource assessment. An exercised collaboration, received contractual payment or new equity financing would alter cash and economic participation. Merlintrader reading: the relevant evidence is the executed transaction and its rights, conditions and net proceeds. The face value of an option or an unused ATM is different from cash already received. September 30, 2026 Form 10-Q, filed November 5

02 The company, RASP modulation and the current development model

Aldeyra is a clinical-stage company developing medicines for immune-mediated diseases. Its platform concerns reactive aldehyde species, or RASP, and their relationship to inflammatory and metabolic processes. Reproxalap is an investigational topical ocular RASP modulator developed for dry eye disease and previously studied in allergic conjunctivitis. No Aldeyra product is approved, and the company has not established a commercial product-revenue base. September 30, 2026 Form 10-Q, filed November 5

The scientific rationale is broader than one conventional receptor target, but each compound and proposed indication needs its own evidence. A mechanism can be plausible while a particular trial fails to show a meaningful clinical effect. The FDA’s reproxalap concerns address the submitted dry-eye efficacy package. They neither validate the entire RASP platform nor supply a controlled conclusion about every other compound or disease. March 16, 2026 FDA complete response letter September 30, 2026 Form 10-Q, filed November 5

Aldeyra’s current organization is small: the September filing reports six full-time employees. It relies on external capabilities and a potential collaboration model for eventual reproxalap commercialization. Merlintrader reading: this can keep current costs relatively low, while a wider development or launch effort would require more internal capability, contractors or a partner. Current expenditure is therefore not a complete budget for every future operating model. September 30, 2026 Form 10-Q, filed November 5

The present portfolio also includes ADX-2191, an intravitreal methotrexate formulation, and the RASP-modulator programs ADX-248 and ADX-246. Their stages, routes and disease populations differ. The November 9 PVRL action materially changes the immediate plan for ADX-2191, while retinitis pigmentosa development is suspended in the quarterly disclosure. ADX-248 is Phase 2-ready after completing Phase 1, rather than already reporting a successful Phase 2 trial. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

Merlintrader reading: Aldeyra combines a heavily tested but disputed lead application with earlier or reset development opportunities. Cash provides room to choose among those paths, not evidence that any one will succeed. The business assessment therefore depends on the FDA requirements, the company’s priorities and the amount of capital necessary to produce interpretable human data. A list of potential indications alone cannot establish the economics of that portfolio. September 30, 2026 Form 10-Q, filed November 5

03 The current regulatory and listing calendar

The completed lead-program milestone is the October 26, 2026 submission of the Formal Dispute Resolution Request to the FDA Office of New Drugs. The November 5 quarterly filing expects an OND meeting in Q4 2026. It does not announce a meeting day, appeal decision day, accepted NDA resubmission or PDUFA target. The request challenges the March CRL, rather than representing an approval application on a new statutory review clock. September 30, 2026 Form 10-Q, filed November 5

The September presentation retains an NDA resubmission after the dispute-resolution decision, with any information required by that outcome. Merlintrader reading: the meaningful sequence is the appeal assessment, the defined evidence response and any later application review. Procedural progress should be connected to the question it resolves rather than assumed to complete the remaining steps. The company describes dispute resolution as discretionary and potentially lengthy. September 29, 2026 regulatory presentation September 30, 2026 Form 10-Q, filed November 5

On November 9, Aldeyra requested that the FDA’s Division of Ophthalmology seek transfer of ADX-2191 PVRL review to the Division of Hematologic Malignancies 2. It simultaneously withdrew the trial protocol previously agreed under the Special Protocol Assessment. It does not expect to begin the planned trial while the request is pending. The submission of the jurisdiction request and the agency’s eventual decision remain outside the company’s unilateral control, with no announced decision date. November 9, 2026 ADX-2191 regulatory disclosure

The November 17 Nasdaq notice creates a separate calendar. The initial minimum-bid compliance period ends May 17, 2027. Listing remains effective; the notice is not a suspension or delisting. The filing specifies the conditions for regaining compliance and a possible second period subject to additional requirements. No particular remedial corporate action was announced. Financial and regulatory progress do not automatically satisfy those listing conditions. November 17, 2026 Nasdaq notice disclosure

Other pipeline guidance is tied to resolution of the FDRR and future company decisions. The old 2027 PVRL initiation objective predates the withdrawn protocol and pending transfer request. Merlintrader reading: a current catalyst calendar needs an actual announced next step, with study initiation, patient enrollment and a data report kept distinct. Historical target windows are context, rather than confirmation that those activities happened. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

04 The reproxalap regulatory history: three review cycles

The original dry-eye NDA was submitted in December 2022. The first CRL arrived in November 2023, with a request for additional adequate and well-controlled evidence of benefit on ocular symptoms. Aldeyra resubmitted in October 2024. The next review cycle ended with a second CRL in April 2025, again centered on symptom efficacy. Acceptance for review in a prior cycle did not resolve the substantive efficacy standard. September 30, 2026 Form 10-Q, filed November 5 September 29, 2026 regulatory presentation

Aldeyra announced a further chamber study in May 2025 that met its primary ocular-discomfort endpoint, with p=0.002, and resubmitted in June. The FDA accepted the response in July and initially assigned a December 2025 action date. A later request for a field-study report was treated as a major amendment, moving the action date to March 16, 2026. The field trial did not meet its primary symptom comparison against vehicle. September 29, 2026 regulatory presentation · May 5, 2025 chamber and field-study results

The third CRL is dated March 16 and was announced March 17. It states that the submitted investigations did not provide substantial evidence of effectiveness for dry-eye signs and symptoms, and identifies inconsistency across studies as a concern for the reliability and meaningfulness of favorable findings. The letter is an adverse agency conclusion about the application, rather than a positive review interrupted by an administrative filing problem. March 16, 2026 FDA complete response letter March 17, 2026 CRL announcement

The company held a Type A meeting June 10, received minutes July 14 and requested clarification July 15. A Type D meeting followed September 25. The September 29 disclosure announced the intended formal appeal; the November quarterly report then confirmed submission October 26. These interactions and the filed request are completed steps, while the outcome and any later resubmission remain unresolved. July 15, 2026 Type A follow-up disclosure September 29, 2026 appeal-plan announcement September 30, 2026 Form 10-Q, filed November 5

Merlintrader reading: the history matters because the recurring issue is evidence of effectiveness. A well-tolerated candidate with positive individual analyses can still fail the application-level standard when the regulator finds the overall pattern unpersuasive. The next development question is what evidence or interpretation the agency will accept, not merely whether the company can obtain another meeting. March 16, 2026 FDA complete response letter September 29, 2026 regulatory presentation

05 Efficacy, clinical consistency and the limits of selected positive findings

Dry-eye trials can assess patient-reported symptoms, ocular signs and responses under different environments. Those measures are related but distinct. A chamber study evaluates a particular controlled exposure and time course; a field trial observes another clinical context. A statistically positive endpoint in one setting does not automatically establish the same effect in another or satisfy every element of a proposed label. The submitted package has to support the intended indication through adequate and well-controlled investigations. March 16, 2026 FDA complete response letter September 29, 2026 regulatory presentation

The March FDA letter identifies unsuccessful studies 012, 019, 023, 030 and 031 and expresses concern that inconsistent results undermine the meaning of positive findings. It recommends examination of reasons for trial failures and the implications for populations and effectiveness. This is the regulator’s assessment. Aldeyra’s September presentation supplies the company’s counterargument that its broader set of controlled studies supports the application. The two positions remain different interpretations of the evidence. March 16, 2026 FDA complete response letter September 29, 2026 regulatory presentation

The company’s argument includes multiple studies, favorable endpoints and a proposed rapid-onset profile. Merlintrader reading: those observations can be relevant without creating a simple tally in which the number of positive outcomes cancels negative trials. Prespecification, multiplicity, endpoint relevance, consistency and the population tested all affect how much confidence a result warrants. A secondary or selected analysis has a different role from a prospectively successful primary endpoint. September 29, 2026 regulatory presentation March 16, 2026 FDA complete response letter

The March response did not identify safety or manufacturing issues as the reason for the action, according to the contemporaneous disclosure. That narrows the principal dispute to efficacy; it is not a declaration that a candidate with an unresolved application is approved or risk-free. Continued clinical and regulatory scrutiny remains necessary for any future indication and commercial label. March 17, 2026 CRL announcement September 30, 2026 Form 10-Q, filed November 5

Merlintrader reading: the stronger future evidence would address the actual reasons for disagreement: which trial findings are reliable, which population and outcomes support use, and what additional work is needed. Repeating the best p-value without its study setting would leave the core problem unresolved. The appeal is valuable only to the extent that it produces a credible, executable route through those questions. March 16, 2026 FDA complete response letter September 30, 2026 Form 10-Q, filed November 5

06 Formal dispute resolution and the subsequent NDA step

A Formal Dispute Resolution Request seeks review of a scientific or regulatory disagreement through the FDA’s management process. Aldeyra filed its request with OND October 26, appealing the March reproxalap CRL. A request, a meeting, an appeal decision and a resubmitted NDA are separate events. The current corporate expectation for a Q4 meeting supplies a window, rather than an exact agency decision date. September 30, 2026 Form 10-Q, filed November 5 September 29, 2026 appeal-plan announcement

The September plan explicitly anticipates resubmitting the NDA after the FDRR decision with any additional information required. A favorable appeal could therefore improve the evidence path while leaving the preparation and review of that response unfinished. An unfavorable assessment could require further analyses or studies, but it does not identify a particular new trial as an automatic consequence before the agency’s actual requirements are known. September 29, 2026 regulatory presentation

Dispute resolution may involve questions, consultation or escalation to further levels. General response goals in guidance are procedural objectives, rather than a guaranteed approval clock. Merlintrader reading: the duration depends on the accepted question, information needed and how the agency handles the disagreement. Converting a general response target into a fixed PDUFA-style countdown would assign more certainty than the current process provides. September 30, 2026 Form 10-Q, filed November 5

The possible outcomes also have different financing implications. Limited additional work could fit a smaller development plan, while another substantial controlled trial could require new sites, participants, manufacturing and follow-up. The company’s runway forecast is based on projected activities; it is not a commitment to complete every possible evidence program for the same cost. Merlintrader reading: the useful financial update follows the actual requirement and its budget, rather than treating every appeal branch as economically equivalent. September 30, 2026 Form 10-Q, filed November 5

A further distinction concerns the partner. A favorable FDRR result does not itself satisfy an FDA-approval condition in the AbbVie arrangement. Nor does an unexercised commercial option bind the agency’s scientific review. Merlintrader reading: the regulatory path, the partner’s exercise decision and the resulting contractual payments form a sequence of conditional events. Their full economic terms appear in chapter 07. September 30, 2026 Form 10-Q, filed November 5

07 AbbVie: received option fees and conditional collaboration economics

The October 2023 agreement gave AbbVie an exclusive option for a co-exclusive U.S. reproxalap collaboration and an exclusive license outside the United States. AbbVie paid $1 million for the option and another $5 million for the December 2023 extension. Those payments have already been received and appear as $6 million deferred collaboration revenue at September 30, 2026. They are not a new financing expected to arrive after the appeal. September 30, 2026 Form 10-Q, filed November 5

The proposed collaboration would provide a $100 million upfront payment less the previously paid option and extension fees. Merlintrader calculation: the two disclosed credits total $6 million, leaving $94 million of incremental upfront payment if the agreement is executed on those terms. That calculation describes a conditional contract payment, not current available cash or an unconditional AbbVie commitment to exercise. The option remained unexercised as of November 5. September 30, 2026 Form 10-Q, filed November 5

Aldeyra would also be eligible for up to approximately $300 million in regulatory and commercial milestones, including a $100 million FDA-approval milestone. The approval milestone is inside that maximum, rather than another $100 million added to it. U.S. commercialization profits and losses would be shared 60% to AbbVie and 40% to Aldeyra; outside the United States, Aldeyra would receive specified tiered royalties. A profit-and-loss share is different from a royalty on gross sales. September 30, 2026 Form 10-Q, filed November 5

The exercise opportunity extends to ten business days following FDA approval of the dry-eye NDA, if approval occurs; earlier exercise remains possible under the agreement. AbbVie gives notice if it elects not to exercise. Precommercial planning does not demonstrate exercise. Certain eligible Aldeyra launch expenses could receive 60% reimbursement after exercise and execution; absent that collaboration, Aldeyra remains responsible for its costs. The company reported no related launch activity or expense in the first nine months of 2026. September 30, 2026 Form 10-Q, filed November 5

Merlintrader reading: the option is potentially important because it combines resources, commercial capability and a defined economic framework. Its present value remains conditional on approval, exercise and execution. The company cannot count the full upfront and milestone package as a replacement for the efficacy evidence, and it cannot add past option fees to current cash a second time. Another partner or an independent launch would carry different terms and resource requirements. September 30, 2026 Form 10-Q, filed November 5

08 The other pipeline: PVRL reset, suspended retina work and newer compounds

ADX-2191 is an intravitreal methotrexate formulation with a distinct regulatory history from reproxalap. Its PVRL NDA received a CRL in June 2023 for insufficient effectiveness evidence from adequate and well-controlled studies. The subsequent Special Protocol Assessment addressed a planned trial’s design and analysis, rather than marketing approval or demonstrated efficacy. The company withdrew the protocol previously submitted under the Special Protocol Assessment in connection with the November 9 jurisdiction request and no longer benefits from that design and analysis agreement. November 9, 2026 ADX-2191 regulatory disclosure

Aldeyra asked the Division of Ophthalmology to seek OND transfer of IND review to the Division of Hematologic Malignancies 2, which typically reviews lymphoma applications. The transfer has not been granted. The company does not expect to initiate the planned trial while the request is pending and expects redesign. A new division would not be bound by the prior division’s positions and could seek different or additional evidence. The filing warns of significant delay, higher cost and possible effects on other regulatory interactions. November 9, 2026 ADX-2191 regulatory disclosure

The PVRL registry was updated November 16, 2026. It retains a recruiting status, with status verification dated January 2026, while listing an estimated December 2027 start, December 2029 completion and 20 participants. The November 9 company filing says the planned trial is not expected to start while the jurisdiction request is pending. Merlintrader reading: the recruiting label is therefore different from evidence of actual trial initiation or dosing. Estimated dates remain planning fields; redesign, the regulatory route and an actual start would be separate execution milestones. Rare-disease enrollment and endpoint reliability remain material challenges. ADX-2191 PVRL registry NCT07402876 November 9, 2026 ADX-2191 regulatory disclosure

The Q3 filing reports suspension of ADX-2191 retinitis pigmentosa clinical development. Earlier small human studies are historical evidence, not proof that the proposed next-stage trial is currently underway. ADX-248 has completed Phase 1 and is Phase 2-ready. ADX-246 remains an investigational retinal RASP-modulator program. Additional guidance is tied to future development decisions and the FDRR outcome; previous initiation or IND windows are not current completed milestones. September 30, 2026 Form 10-Q, filed November 5

New registry results were posted November 10 for ADRO Part 1, an older open-label ADX-629 study completed November 21, 2023. ADX-629 is a historical signal-finding compound no longer under development. Eight participants were divided into groups of five, two and one. The record reports no serious adverse events in the primary safety outcome over approximately fifteen weeks and reports symptom changes, with different background-treatment settings. This is a historical non-randomized dataset, not an ADX-248 Phase 2 result or controlled evidence of comparative efficacy. November 10, 2026 posted ADRO Part 1 results · Q3 Form 10-Q, historical ADX-629 development status

Merlintrader reading: the portfolio offers development possibilities rather than immediate substitutes for a successful reproxalap application. Each needs adequate resources, an executable regulatory path and interpretable human evidence. A mechanism shared across candidates does not allow one small study to validate all compounds or offset the lead application’s deficiencies. The November PVRL action makes current prioritization and cash planning especially consequential. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

The ADRO groups comprised five participants receiving ADX-629 alone, two with topical standard care and one with dupilumab. All eight completed the study. The posted secondary outcome of at least four-point peak-itch improvement over days 1–90 occurred in five of five, two of two and one of one; Day-90 EASI50, a 50% improvement in eczema area and severity, occurred in four of five, zero of two and zero of one. Non-serious adverse events affected four of five, zero of two and one of one. Merlintrader reading: the tiny, non-randomized groups do not separate treatment effect from background therapy, selection or time. A zero serious-event count also does not mean no adverse events occurred. November 10, 2026 posted ADRO Part 1 results

09 September cash, expenditure and the conditional runway

Aldeyra reported $40,974,979 cash and equivalents at September 30, 2026, with no marketable securities held and no debt obligations outstanding. The balance already reflects repayment of the Hercules facility earlier in the year. It is a reporting-date amount, rather than a reconstructed November cash balance. The financial statements do not report commercial product revenue to fund the present development activities. September 30, 2026 Form 10-Q, filed November 5

The following amounts are USD for the quarter ended September 30, 2026. Operating expense, accounting loss and cash flow measure different aspects of the company’s activity. September 30, 2026 Form 10-Q, filed November 5

Q3 2026 measureUSD
Research and development1,837,390
General and administrative2,298,884
Operating loss4,136,274
Interest income373,748
Interest expense(438)
Net loss3,762,964

For the first nine months, net loss was $12,665,856 and operating cash use $13,824,010. Research and development was $7,731,478 and general and administrative expense $5,802,220. The current expenditure profile includes the company’s selected activities and payment timing. Merlintrader reading: reduced spending can extend practical flexibility, while it does not prove that a future pivotal trial or commercialization program can be conducted for the same amount. September 30, 2026 Form 10-Q, filed November 5

The November 5 report projects operating runway into 2029 based on current plans, including the FDRR process and excluding potential licensing and product revenue. Into 2029 is different from through December 2029. The November 9 disclosure subsequently warns that PVRL redesign and other outcomes could shorten the projected runway and bring forward financing needs. The cash balance, the original forecast and the subsequent risk qualification belong together. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

Merlintrader reading: runway is an operating forecast whose assumptions need to follow the actual regulatory requirements and development priorities. It supplies time to pursue selected objectives, while leaving uncertainty about which objectives will be feasible or productive. A cash-per-share figure or a static division by recent expenditure would not capture those decisions and is not a guaranteed floor for common-share value. September 30, 2026 Form 10-Q, filed November 5

The balance sheet reports $42,918,797 current assets and $7,879,576 current liabilities, including deferred collaboration revenue. Total assets were $43,381,909 and total liabilities $8,159,697, leaving $35,222,212 stockholders’ equity. Merlintrader reading: these accounting measures describe resources and claims with different liquidity and recognition rules; they are not a guarantee that each asset can fund any chosen program or that equity book value protects an investment outcome. September 30, 2026 Form 10-Q, filed November 5

Cash declined $29,066,275 over the first nine months. Operating activities used $13,824,010, investing used $23,097 and financing used $15,219,168. The financing outflow principally reflects the repaid loan and end charge, with small employee-plan receipts. Merlintrader reading: the historical cash decline therefore cannot all be called operating burn, and the already repaid financing cost is not a continuing monthly expense. Future spending follows the development work actually undertaken. September 30, 2026 Form 10-Q, filed November 5

10 Debt repayment, commitments and potential equity financing

Hercules principal of $15 million was repaid April 1, 2026, with a $300,000 end-of-term charge. The September cash balance is after that repayment, and the company reports no debt obligations. Deducting the same principal again would count an already settled obligation twice. Debt-free status still leaves operating costs, lease liabilities and development commitments to be financed from available resources or future receipts. September 30, 2026 Form 10-Q, filed November 5

The September balance sheet includes $178,577 current and $280,121 long-term operating lease liabilities. The Concord headquarters lease runs into September 2029. Rent and other operating commitments are different from funded loan principal, while remaining claims on the operating budget. Merlintrader reading: flexibility depends on the cash needed for the selected plan, not simply whether a bank loan remains outstanding. September 30, 2026 Form 10-Q, filed November 5

The Jefferies ATM agreement permits up to $75 million in common-stock sales. No shares had been sold under that agreement through September 30, 2026. Registered capacity is not an investor commitment, cash already received or a forecast that the entire amount will be issued. Actual sales would have their own timing, costs and share-count consequences. September 30, 2026 Form 10-Q, filed November 5

The balance sheet also contains $6 million deferred collaboration revenue associated with AbbVie’s already received option fees. This is a contract-accounting liability, separate from a conventional loan and from the additional payments conditional on collaboration execution. Full option terms appear in chapter 07. The current-liability classification does not transform the original fee into new cash arriving with the next FDA interaction. September 30, 2026 Form 10-Q, filed November 5

Merlintrader reading: future financing choices depend on what the FDA and the company’s development priorities require. A limited appeal response and a larger new clinical program would imply different funding needs. An equity offering could preserve a program while increasing the denominator; a commercial agreement could bring resources while transferring rights or future economics. Net proceeds and the obligations accepted determine the practical financing benefit. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

11 Common shares, awards and potential dilution

The company reports 60,356,541 common shares outstanding at September 30 and on the November 3 Form 10-Q cover date. That legal count differs from outstanding options, restricted awards and unused plan capacity. Authorized common shares are a corporate limit rather than issued shares, while an effective ATM program creates an offering route rather than an executed financing. Each layer has its own conditions. September 30, 2026 Form 10-Q, filed November 5

At September 30, outstanding options covered 8,886,608 shares and restricted stock units covered 59,688. A further 2,439,770 shares were available under the equity plan and 4,106,821 under the employee-purchase plan. Reserves are different from grants; grants are different from vesting and exercise. Adding every reserve and an overlapping earnings-per-share table would not establish a single certain future common-share count. September 30, 2026 Form 10-Q, filed November 5

The company also uses cash-settled stock-based units. Their value follows specified contractual measures, but they create cash obligations rather than necessarily issuing common shares. Approximately $1.2 million of earlier cash-unit awards was paid in Q3, while newer liability-based awards had a separate accrued balance. Merlintrader reading: compensation can consume resources through cash or economic participation, so lower equity issuance does not automatically mean lower total compensation cost. September 30, 2026 Form 10-Q, filed November 5

Loss-per-share dilution accounting also differs from ownership exposure. Potential securities may be excluded when their inclusion would be anti-dilutive in a loss period, without eliminating possible future issuance. Ordinary common outstanding, a weighted earnings denominator and an assumed fully exercised capital structure answer different questions. Merlintrader reading: the proper assessment follows each instrument’s rights, conditions and cash consequences instead of treating every reported quantity as an additional current share. September 30, 2026 Form 10-Q, filed November 5

Merlintrader reading: the central trade-off is the capital needed to reach useful evidence against the rights retained per existing share. The into-2029 outlook can reduce near-term pressure under current assumptions, but a more demanding trial program or delayed partner outcome can change those assumptions. Neither the current cash balance nor the unused ATM establishes the terms of any future funding. September 30, 2026 Form 10-Q, filed November 5 November 9, 2026 ADX-2191 regulatory disclosure

The reported share-compensation expense was $1,114,104 in Q3 and $1,769,550 in the first nine months. This expense measure is separate from changes in additional paid-in capital and from cash paid to settle liability-classified bonus units. Merlintrader reading: the distinction helps explain why accounting expense, cash use and issued-share changes do not move in parallel. Evaluating compensation requires the terms and settlement method of the particular award. September 30, 2026 Form 10-Q, filed November 5

12 Ownership, genuine insider purchases and Nasdaq compliance

Ownership filings report dated beneficial interests, which can overlap across a manager, subsidiaries and controlling persons. The filing date differs from the date of any underlying transaction or measured position. Percentages also depend on the reporting security and denominator. Merlintrader reading: those definitions matter when assessing concentration, but an institution’s disclosed holding is not evidence that the FDA agrees with the company’s appeal. September 30, 2026 Form 10-Q, filed November 5

Three November Forms 4 report genuine code P purchases. Director Richard Douglas acquired 200,000 shares November 11, ending with 395,000; Principal Financial Officer Michael Alfieri acquired 10,000 the same day, ending with 17,500. Both were filed November 13. Director Darlene Deptula-Hicks acquired 7,500 November 12, ending with 7,500, in the November 16 filing. These are different from awards, option exercises or shares retained for taxes. The disclosed purchases do not provide operating financing to Aldeyra. November 13, 2026 Douglas Form 4 November 13, 2026 Alfieri Form 4 November 16, 2026 Deptula-Hicks Form 4

Merlintrader reading: purchases with personal capital can be relevant to alignment and incentives without predicting an agency decision or validating a clinical endpoint. Their significance is distinct from a share grant and from the company’s receipt of capital. The regulatory and funding assessment still depends on the actual evidence, obligations and cash flows. November 13, 2026 Douglas Form 4 November 13, 2026 Alfieri Form 4 November 16, 2026 Deptula-Hicks Form 4

The November 17 Nasdaq notice concerns the $1 minimum-bid rule after the required period below that threshold. It has no immediate effect on listing, with an initial compliance period to May 17, 2027. The stated cure requires at least ten consecutive qualifying business days, and a possible second period has further conditions. This is a listing deficiency, rather than a completed delisting or a newly announced reverse split. November 17, 2026 Nasdaq notice disclosure

The October 30 settlement data report 3,159,816 shares short, average daily volume of 917,902 and published days to cover of 3.44. These are dated positioning and volume measures, rather than real-time borrowing or a forecast of covering. Merlintrader reading: regulatory news and trading structure can produce sensitivity while giving no independent evidence about a successful appeal or secured financing. October 30, 2026 short-interest settlement data

Barclays’ November 6 Schedule 13G reports 3,310,587 beneficial shares and 5.48% at September 30. Its listed subsidiaries do not represent additional separate blocks to add to that total. AQR’s November 12 amendment reports 672,616 shares and 1.11% at September 30, with overlapping manager and holding-company reporting persons. These reports measure beneficial ownership at a date, rather than transactions on the filing dates or evidence of an activist strategy. November 6, 2026 Barclays Schedule 13G November 12, 2026 AQR Schedule 13G/A

13 Red flags and the evidence behind the assessment

The September Form 10-Q also describes a securities class action filed March 30, 2026 in the U.S. District Court for the District of Massachusetts against the company and certain current and former officers. An amended complaint was filed October 9, alleging misleading statements or omissions concerning the reproxalap application and prospects. These are allegations. The company could not predict the outcome or estimate potential losses. Q3 Form 10-Q, legal proceedings.

The central scientific disagreement remains. Three reproxalap CRLs culminated in the March 2026 challenge to the efficacy package. The filed appeal is a concrete procedural step, while the outcome, subsequent application requirements and any approval remain separate. Positive selected trials do not erase the regulator’s assessment of inconsistency. March 16, 2026 FDA complete response letter September 30, 2026 Form 10-Q, filed November 5

Pipeline plans have materially changed. PVRL’s SPA trial protocol has been withdrawn, review transfer is only requested and planned initiation is not expected while pending. Retinitis pigmentosa work is suspended; earlier-stage programs need human evidence and current guidance. The November 9 risks can also affect cost and runway assumptions. November 9, 2026 ADX-2191 regulatory disclosure September 30, 2026 Form 10-Q, filed November 5

Cash and contractual optionality have limits. September cash and debt repayment support flexibility, while future licensing payments, milestone maxima and ATM capacity are not interchangeable with received funds. Nasdaq compliance adds a separate dated requirement. September 30, 2026 Form 10-Q, filed November 5 November 17, 2026 Nasdaq notice disclosure

Merlintrader reading: Aldeyra’s current case combines time to pursue selected objectives with unusually persistent regulatory uncertainty in its lead program. The constructive path would clarify the evidence needed, execute that plan and connect approval to workable commercial economics. The adverse path would consume more resources without resolving the efficacy standard. Each future development is most useful when it reduces a specific uncertainty rather than merely repeating the size of the potential market or partner headline. September 30, 2026 Form 10-Q, filed November 5 March 16, 2026 FDA complete response letter

Merlintrader Health Score · $ALDX

2.35out of 5
Balance sheet and runway · 30%3.5 / 5

At September 30 cash and equivalents were $40,974,979 and Aldeyra reported zero debt obligations. Operating cash use was $13,824,010 over nine months. The runway forecast into 2029 is conditional, and the November 9 filing identifies risks to the spending plan.

Catalysts · 30%2 / 5

Aldeyra submitted the appeal on October 26 and anticipates a Q4 Office of New Drugs meeting. A future decision, resubmission and FDA action remain separate.

Dilution · 20%2 / 5

The November 3 cover lists 60,356,541 common shares. The $75 million ATM had no sales by September 30. Outstanding awards and future financing could add shares.

Trading liquidity · 10%1.5 / 5

October 30 data reported 3,159,816 shares short with average daily volume of 917,902 shares and 3.44 days to cover. The Nasdaq notice sets an initial deadline of May 17, 2027.

Execution · 10%1.5 / 5

Reproxalap has received three complete response letters. Aldeyra withdrew the primary vitreoretinal lymphoma trial protocol previously agreed under the SPA and sought a change in FDA review division.

Reassessed November 18, 2026. Merlintrader calculation: 3.5×30% + 2×30% + 2×20% + 1.5×10% + 1.5×10% = 2.35/5. September Form 10-Q · November 9 Form 8-K · November 17 Form 8-K · October 30 short-interest settlement data. The score describes financial and operating robustness and carries no investment recommendation.

Red flags

  • The appeal outcome and timing are uncertain.
  • No accepted new application or PDUFA date is established by the appeal plan.
  • Historical cash and a runway forecast do not demonstrate current liquidity or efficacy.
  • Further evidence requirements, trials and future equity issuance can change costs and ownership.
  • For ADX-2191 in PVRL the trial protocol previously agreed under the Special Protocol Assessment was withdrawn and the IND review transfer requested on November 9 is not granted; the company says the path is uncertain, may be significantly delayed and could affect its dealings with the FDA on other programs.
  • On November 17, 2026 Nasdaq notified Aldeyra that it does not meet the $1.00 minimum bid price requirement; without compliance by May 17, 2027, or a second compliance period, the listing on The Nasdaq Capital Market is at risk. Form 8-K, November 17, 2026

ALDX Stock FAQ: Aldeyra Therapeutics Questions Answered

When is the next ALDX stock catalyst?

As of November 17, 2026, Aldeyra expected a Q4 Office of New Drugs meeting on the reproxalap appeal. The November 17 listing notice separately sets an initial compliance deadline of May 17, 2027. Quarterly filing · November 17 Form 8-K.

Is Aldeyra Therapeutics’ reproxalap FDA approved?

As of November 17, 2026, reproxalap remained investigational. The October 26 request appeals the March complete response letter. Aldeyra expects a Q4 Office of New Drugs meeting. Regulatory status in Form 10-Q.

How much cash does Aldeyra have, and how long will it last?

Aldeyra reported $40,974,979 of cash and equivalents and no debt obligations at September 30, 2026. Its plan forecasts funds into 2029, excluding potential licensing or product revenue. The November 9 filing warns that further development and financing demands could shorten the projected runway. September Form 10-Q · November 9 Form 8-K.

Is ALDX stock at risk of dilution?

Aldeyra reported 60,356,541 common shares at November 3, 2026. Its September filing showed no sales through September 30 under the $75 million ATM. Equity awards and potential future issuance remain separate exposures. Shares and ATM disclosure.

When does Aldeyra Therapeutics report earnings?

Aldeyra filed its September-quarter 2026 Form 10-Q on November 5. As of November 17, the company had yet to announce a next financial reporting date. September Form 10-Q · Company announcements.

What does Aldeyra Therapeutics do?

Aldeyra develops medicines for immune-mediated diseases. Its lead candidate reproxalap targets dry eye disease and remains investigational after an FDA complete response letter. Its development portfolio also includes ADX-248, which has completed Phase 1 and is Phase 2-ready; the Q3 Form 10-Q reports the suspension of the ADX-2191 retinitis pigmentosa clinical development program, and on November 9, 2026 the company asked for the ADX-2191 IND in primary vitreoretinal lymphoma to be reviewed by a different FDA division and withdrew the trial protocol previously agreed under the Special Protocol Assessment. Company and lead candidate. Form 8-K, November 9. Development portfolio (Q3 Form 10-Q).

Is Aldeyra’s FDA appeal the same as resubmitting the reproxalap NDA?

No: Aldeyra’s September 29, 2026 presentation retains a subsequent NDA resubmission step after the appeal decision. Formal dispute resolution and an application resubmission are different procedures. The request was submitted on October 26, 2026, and the OND meeting is expected in Q4 2026, according to the Q3 Form 10-Q. Appeal and subsequent resubmission steps. Announced procedural expectations.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ALDX or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

This content is for informational and educational purposes only and does not constitute investment advice, financial advice, personalized recommendation, solicitation, or an instruction to buy, sell, short, hold or trade any security. Biotech and small-cap stocks can be highly volatile and may involve clinical trial failure, regulatory rejection, dilution, liquidity risk, market manipulation risk, analyst-estimate risk and total loss of capital. All investigational therapies discussed here remain subject to regulatory review and may never be approved or commercialized. Readers should verify all facts directly through SEC filings, company releases, FDA materials and other primary sources, and should consult a qualified financial professional before making investment decisions. Merlintrader may publish educational and editorial content about securities but does not provide personalized investment recommendations.